Nemours Children's Health System - Corporate Headquarters — Pensacola, Florida

Nemours Children's Health System - Corporate Headquarters is a clinical research site located in Pensacola, Florida, United States 32514.

Crixeo Clinical Trials Trust Score: 11/100 (FAILING). This profile has not yet been claimed by the site owner.

Nemours Children's Health System - Corporate Headquarters has participated in 2 clinical trials with 2 currently active.

Therapeutic areas: Idiopathic Short Stature.

Sponsors: BioMarin Pharmaceutical.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Pensacola

Browse all research sites in Florida · View every site in Pensacola

Sponsor Feasibility Report

Trust Score: 11/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Nemours Children's Health System - Corporate Headquarters?

Nemours Children's Health System - Corporate Headquarters has a Crixeo Trust Score of 11/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Nemours Children's Health System - Corporate Headquarters conducted?

Nemours Children's Health System - Corporate Headquarters has 2 clinical trials on record, with 2 currently active. Their work covers Idiopathic Short Stature.

Is Nemours Children's Health System - Corporate Headquarters accredited by Crixeo Clinical Trials?

Nemours Children's Health System - Corporate Headquarters has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Nemours Children's Health System - Corporate Headquarters?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.